MedPath

The University Of Texas Health Science Center At San Antonio

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Effects of Canagliflozin on Intravascular Volume and Hemodynamics

Phase 4
Withdrawn
Conditions
Cardiovascular Diseases
Type2 Diabetes Mellitus
Interventions
First Posted Date
2017-06-19
Last Posted Date
2017-10-12
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Registration Number
NCT03190798
Locations
🇺🇸

The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria

First Posted Date
2017-05-30
Last Posted Date
2020-09-17
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
34
Registration Number
NCT03168295
Locations
🇺🇸

The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

TRanslesIonal Assessment of Gradients During Endovascular Therapy

Completed
Conditions
Hemodynamics
Fractional Flow Reserve
Peripheral Arterial Disease
First Posted Date
2017-05-22
Last Posted Date
2022-02-18
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
22
Registration Number
NCT03163199
Locations
🇺🇸

University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions

Recruiting
Conditions
Pheochromocytoma
Paraganglioma
Associated Conditions
Inherited Cancer Syndrome
Kidney Neoplasms
Bone Cancer
Thyroid Neoplasms
Other Cancer
First Posted Date
2017-05-19
Last Posted Date
2023-09-26
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
2000
Registration Number
NCT03160274
Locations
🇺🇸

University of Texas Health Science Center, San Antonio, Texas, United States

Imipramine on ER+ve and Triple Negative Breast Cancer

Early Phase 1
Completed
Conditions
Breast Cancer
Interventions
First Posted Date
2017-04-20
Last Posted Date
2023-06-28
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
17
Registration Number
NCT03122444
Locations
🇺🇸

Mays Cancer Center, UT Health San Antonio, San Antonio, Texas, United States

Rectal Misoprostol as a Hemostatic Agent During Abdominal Myomectomy

Phase 4
Completed
Conditions
Myomectomy; Surgical Blood Loss
Interventions
First Posted Date
2017-02-27
Last Posted Date
2024-12-13
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
18
Registration Number
NCT03064568
Locations
🇺🇸

St. Lukes Baptist Hospital, San Antonio, Texas, United States

🇺🇸

University Hospital, San Antonio, Texas, United States

🇺🇸

University of Texas Health Science Center, San Antonio, Texas, United States

Rapid PCR to Guide Antibiotic Therapy at the Time of Prostate Biopsy

Not Applicable
Completed
Conditions
Antibiotic Therapy
Prostate Biopsy
Interventions
Other: rPCR results
Other: Control group
First Posted Date
2017-02-01
Last Posted Date
2020-02-05
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
38
Registration Number
NCT03040050
Locations
🇺🇸

South Texas Veterans Health Care, San Antonio, Texas, United States

Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer

Phase 2
Active, not recruiting
Conditions
Hepatocellular Cancer
Interventions
First Posted Date
2017-01-31
Last Posted Date
2024-08-13
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
64
Registration Number
NCT03037437
Locations
🇺🇸

University of Texas Health Cancer Center, San Antonio, Texas, United States

TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma

Phase 2
Completed
Conditions
Astrocytoma
Interventions
First Posted Date
2017-01-26
Last Posted Date
2023-06-15
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
25
Registration Number
NCT03032484
Locations
🇺🇸

University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center, San Antonio, Texas, United States

Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

Phase 2
Withdrawn
Conditions
BRCA1 Mutation
Breast Cancer Stage IV
Ovarian Cancer
BRCA2 Mutation
Interventions
First Posted Date
2017-01-26
Last Posted Date
2017-10-10
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Registration Number
NCT03032614
© Copyright 2025. All Rights Reserved by MedPath